Valensa Begins Licensing Patent for Astaxanthin in Eye Health Management

Zanthin(R) Natural Astaxanthin Has Excellent Market Potential for Baby Boomers
and Other Consumers

ORLANDO, Fla., Oct. 8 /PRNewswire/ -- Valensa International (Orlando, FL USA)
announced today that it has initiated a broad out licensing effort for
University of Illinois patent (US 5,527,533 and its foreign equivalents) for
the use of the astaxanthin in eye healthcare dietary supplement applications.
FutureBiotics (NY, USA), Swanson Health Products (ND, USA) and Life Extension
Vitamins (AZ, USA) have each acquired licenses for the use of the Valensa
astaxanthin patent. The patent covers the use of astaxanthin as a dietary
supplement for amelioration of free radical- and light-induced retinal damage,
age-related macular degeneration, photoreceptor cell retinal damage and damage
to neurons of inner retinal layers, among other claims. Licensing agreements
feature the use of Valensa's Zanthin(R) natural astaxanthin extract - a
proprietary formulation of microalgae extracted using ultra-high pressure
supercritical CO2 in an allergen-free certified organic facility in Florida,
protected with Valensa's state-of-the art O2B(TM) stabilization technology,
with the final product ensuring efficacy with a 4-year shelf life. Valensa,
the only full-integrated supplier of astaxanthin extract in the United States,
has been a leader in acquiring regulatory approvals for its astaxanthin
product in the United States and Europe. Valensa also recently announced that
it is working on eye health formulations that incorporate both Zanthin(R)
natural astaxanthin and Neptune Technologies & Bioressources' advanced Omega-3
ingredient, NKO(R) Krill Oil.

According to Dr. Rudi E. Moerck, President & CEO of Valensa, the availability
of efficacious, proven eye health support is at the top of the list of health
concerns of a growing segment of the global population. "Eye health is a major
concern for aging baby boomer populations of the United States, Europe and
parts of Asia. Today, nearly 30% of Americans over the age of 55 suffer from
visual impairment due to age-related eye health disorders - primarily
cataracts and age-related macular degeneration (ARMD) - both of which are
primary causes of blindness," he said. "While lutein and zeaxanthin are often
promoted as leading eye health supplement ingredients, numerous scientific
studies have shown that astaxanthin is by far the most effective carotenoid in
addressing the free-radical and light-induced singlet oxygen damage associated
with visual impairment. With its ability to cross the blood-brain/blood-eye
barriers and to concentrate in the central cones of the retinal macula,
astaxanthin is now emerging as the pre-eminent solution for eye healthcare
supplementation in the management of retinal oxidative stress that would lead
to macular degeneration," he added.

Making the Eye-Health Claim with Astaxanthin

Recent research strongly supports astaxanthin as the eye healthcare supplement
of choice due to its ability to cross the blood-brain/blood-retina barrier and
preferentially reside in the cones of the foveal region of the macula.
Research also points to astaxanthin's exceptional reduction on light-induced
oxidative stress processes that damage cells and many cellular mechanisms.
Astaxanthin was found to be many times more effective than either
beta-carotene or lutein against UV light induced cellular damage. Results from
the CARMIS clinical trial (Carotenoids and Antioxidant in Age Related
Maculopathy Italian Study), which employed astaxanthin as a critical component
ingredient, strongly suggests that astaxanthin is an excellent addition to eye
healthcare supplements that may already contain lutein. Lutein is known to
accumulate in the outer region of the macula, where light impingement is
relatively low in comparison to the central macular region (also known as the
fovea) where the highest light impingement always occurs and where maximum
anti-oxidant protection is required. In addition, unlike the AREDS
(Age-Related Eye Disorder Study), conducted by the US National Eye Institute,
carotenoid ingredients like lutein, as well as water-soluble vitamins such as
A and C, can become dangerously pro-oxidant; whereas, astaxanthin essentially
never acts as a pro-oxidant, even at high concentrations. The bottom line is
that ARMD studies to date require the inclusion of patients with ARMD in at
least one eye and are not designed to show prevention prior to a disease
state. Supplementation with astaxanthin (2 mg) and eating a healthful diet
full of fruits and vegetables, naturally rich in antioxidants like lutein and
zeaxanthin, are good prevention measures against eye health damage.

According to Valensa's Moerck, supplement marketers around the world have the
opportunity to tap into the demand for better eye healthcare products with
Valensa's growing patent position in astaxanthin and NKO(R) krill-based
products. "Better eye health is a very powerful message for the retail
audience. Particularly in a time when baby boomers are looking to 'age
gracefully,' regular supplementation with a Zanthin-based eye healthcare
product has the opportunity to be the 'next big thing' in eye healthcare," he
said. "Today, Valensa stands ready with the highest quality astaxanthin
products on the market and is looking forward to further licensing of this
technology to supplement manufacturers and markets around the world," he
added.

For further information, contact:

Dr. Rudi Moerck, President & CEO
Voice: 352-357-2004 ext. 701
Fax: 352-483-2095
http://www.valensa.com

This release was issued through eReleases(TM). For more information, visit
http://www.ereleases.com.

SOURCE Valensa International

Dr. Rudi Moerck, President & CEO of Valensa, +1-352-357-2004 ext. 701, Fax:
+1-352-483-2095